





□

□

□



□







□

□

□

□

□



□

□













□











□



□



□

□

□

□



<a href="#">Table of Contents</a>	<a href="#">RSS</a>	<a href="#">Home</a>	<a href="#">Back Issues</a>	<a href="#">Indexes</a>
2011 SEPTEMBER–OCTOBER	No. 382			

October 25, 2011 [posted]

## New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI)

The National Heart, Lung, and Blood Institute (NHLBI) issued a new Clinical Alert on October 21, 2011:

Commonly Used Three-drug Regimen for Idiopathic Pulmonary Fibrosis Found Harmful: *NIH Stops One Treatment Arm of Trial; Other Two Treatments to Continue*

NHLBI has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.

Links to Clinical Alerts/Advisories can also be found from these NLM® Web sites:

- A complete list of all Clinical Alerts/Advisories is available from the NIH Clinical Alerts and Advisories page on the NLM Web site.
- MedlinePlus® features Clinical Alerts/Advisories as NIH Press Releases on the appropriate Health Topics page(s).
- PubMed®, the NLM Gateway and ClinicalTrials.gov each have access points to the Clinical Alerts/Advisories.

---

*New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI). NLM Tech Bull. 2011 Sep-Oct;(382):e15.*

<a href="#">PREVIOUS</a>	2011 SEPTEMBER–OCTOBER	No. 382			
<a href="#">Stay Current <input checked="" type="checkbox"/></a>			<a href="#">Home</a>	<a href="#">Back Issues</a>	<a href="#">Indexes</a>

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894  
National Institutes of Health, Department of Health & Human Services  
Copyright, Privacy, Accessibility  
Freedom of Information Act (FOIA)